Join us as we explore the innovations that defined 2025—and what they mean for the future of the field.

Ultragenyx Pharmaceuticals reported Phase 3 results for setrusumab, a potential treatment for osteogenesis imperfecta.

As of Tuesday, December 30, Ultragenyx Pharmaceutical Inc.’s RARE share price has surged by 9.99%, which has investors questioning if this is right time to sell.

As of Monday, December 29, Praxis Precision Medicines, Inc.’s PRAX share price has surged by 15.27%, which has investors ...

Final results from the VALOR trial and its open-label extension demonstrated the clinical benefit of tofersen in adults with ...

Leading RNA drug developer Suzhou Ribo Life Science Co. Ltd. passed its hearing for a listing on the Hong Kong Stock Exchange, marking the official launch of its IPO, according to its post-hearing ...

A dedicated bioimaging function at GSK has shown how integrated microscopy and analytics can deliver quantitative evidence ...

From AI simulations to energy-efficient manufacturing, learn how leaders in academia and industry are conducting responsible, ...

Detailed price information for Praxis Precision Medicines Inc (PRAX-Q) from The Globe and Mail including charting and trades.

Department of Applied Chemistry, Graduate School of Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan Advanced Transdermal Drug Delivery System Center, Kyushu University, ...